Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Melanoma Melanoma for November/December 2020 Phase 1 study: Beta-blocker may improve melanoma treatment response, ‘Impressive’ results with neoadjuvant T-VEC in advanced melanoma, Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest, Neoadjuvant immunotherapy combo produces high response rate in melanoma, Vaccine regimen boosts immune response in malignant melanoma, More must reads Melanoma for September/October 2020 ‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients, Fatal pediatric melanomas diverse in presentation, More must readsMelanoma for July/August 2020 VTE, sepsis risk increased among COVID-19 patients with cancer, Aspirin may accelerate cancer progression in older adults, Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19, CCC19, other registries help define COVID-19/cancer landscape, Real-world data support adjuvant immunotherapy for stage III melanoma, More must readsMelanoma for May/June 2020 Personalized cancer vaccine may enhance checkpoint inhibitor activity, Study evaluates number of needed to refer, biopsy for diagnosing a melanoma, Vulvar melanoma is increasing in older women, Combo exhibits activity in metastatic mucosal melanoma, Adding low-dose ipi to pembro seems safer, still effective for advanced melanoma, More must readsMelanoma for March/April 2020 Cancer prevalence among COVID-19 patients may be higher than previously reported, Teledermoscopy using smartphones fails to boost skin cancer detection, Patients accept artificial intelligence in skin cancer screening, More must readsPages1 2 3 4 5 last »
